Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Clinical trial NCT05996523 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05996523
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-07
- Primary completion
- 2025-05-22
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.